Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas.
作者： L. Doherty , D. C. Gigas , S. Kesari , J. Drappatz , R. Kim
DOI: 10.1212/01.WNL.0000223844.77636.29
关键词:
摘要: Malignant gliomas are frequently characterized by amplification of the epidermal growth factor receptor (EGFR) and loss PTEN tumor suppressor gene. Twenty-eight heavily pretreated patients with recurrent malignant were administered EGFR inhibitors (gefitinib or erlotinib) in combination mTOR (mammalian target rapamycin) inhibitor sirolimus. The regimens reasonably well tolerated. Nineteen percent experienced a partial response 50% had stable disease. Six-month progression-free survival for glioblastoma was 25%.
elsevier.com
sci-hub.se 参考文章(8)
Eric T. Wong, Kenneth R. Hess, Mary Jo Gleason, Kurt A. Jaeckle, Athanassios P. Kyritsis, Michael D. Prados, Victor A. Levin, W.K. Alfred Yung, Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials Journal of Clinical Oncology. ,vol. 17, pp. 2572- 2578 ,(1999) , 10.1200/JCO.1999.17.8.2572
D R Macdonald, T L Cascino, S C Schold, J G Cairncross, Response criteria for phase II studies of supratentorial malignant glioma. Journal of Clinical Oncology. ,vol. 8, pp. 1277- 1280 ,(1990) , 10.1200/JCO.1990.8.7.1277
Jeffrey J. Raizer, HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme Journal of Neuro-oncology. ,vol. 74, pp. 77- 86 ,(2005) , 10.1007/S11060-005-0603-7
Ingo K Mellinghoff, Maria Y Wang, Igor Vivanco, Daphne A Haas-Kogan, Shaojun Zhu, Ederlyn Q Dia, Kan V Lu, Koji Yoshimoto, Julie HY Huang, Dennis J Chute, Bridget L Riggs, Steve Horvath, Linda M Liau, Webster K Cavenee, P Nagesh Rao, Rameen Beroukhim, Timothy C Peck, Jeffrey C Lee, William R Sellers, David Stokoe, Michael Prados, Timothy F Cloughesy, Charles L Sawyers, Paul S Mischel, None, Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. The New England Journal of Medicine. ,vol. 353, pp. 2012- 2024 ,(2005) , 10.1056/NEJMOA051918
Evanthia Galanis, Jan C. Buckner, Matthew J. Maurer, Jeffrey I. Kreisberg, Karla Ballman, J. Boni, Josep M. Peralba, Robert B. Jenkins, Shaker R. Dakhil, Roscoe F. Morton, Kurt A. Jaeckle, Bernd W. Scheithauer, Janet Dancey, Manuel Hidalgo, Daniel J. Walsh, Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study Journal of Clinical Oncology. ,vol. 23, pp. 5294- 5304 ,(2005) , 10.1200/JCO.2005.23.622
Elizabeth A Maher, Frank B Furnari, Robert M Bachoo, David H Rowitch, David N Louis, Webster K Cavenee, Ronald A DePinho, Malignant glioma: Genetics and biology of a grave matter Genes & Development. ,vol. 15, pp. 1311- 1333 ,(2001) , 10.1101/GAD.891601
Ranjit K Goudar, Qing Shi, Mark D Hjelmeland, Stephen T Keir, Roger E McLendon, Carol J Wikstrand, Elizabeth D Reese, Charles A Conrad, Peter Traxler, Heidi A Lane, David A Reardon, Webster K Cavenee, Xiao Fan Wang, Darell D Bigner, Henry S Friedman, Jeremy N Rich, None, Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Molecular Cancer Therapeutics. ,vol. 4, pp. 101- 112 ,(2005)
Susan M. Chang, , Patrick Wen, Timothy Cloughesy, Harry Greenberg, David Schiff, Charles Conrad, Karen Fink, H. Ian Robins, Lisa De Angelis, Jeffrey Raizer, Kenneth Hess, Ken Aldape, Kathleen R. Lamborn, John Kuhn, Janet Dancey, Michael D. Prados, Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Investigational New Drugs. ,vol. 23, pp. 357- 361 ,(2005) , 10.1007/S10637-005-1444-0